Streamlining Eylea Prior Authorization for Orthopedics Workflows

While Eylea (aflibercept) is an anti-VEGF intravitreal injection indicated for ophthalmic conditions like wet AMD and diabetic macular edema, managing its specialty prior authorization within a health system that also handles high-volume orthopedic PA presents distinct administrative challenges.

Health systems and multi-specialty clinics frequently navigate a complex landscape of prior authorization requirements spanning diverse clinical areas. The administrative burden of processing specialty drug PAs, such as for Eylea, alongside the intricate demands of orthopedic procedures and imaging, necessitates robust automation to maintain operational efficiency and patient access.

Understanding Eylea (Aflibercept) Prior Authorization

Eylea (aflibercept) is a critical anti-VEGF therapy for specific retinal conditions. As a specialty drug, its prior authorization typically involves detailed clinical documentation to confirm indications like wet AMD, diabetic macular edema, or retinal vein occlusion. These are often 'buy-and-bill' medications, requiring careful inventory and reimbursement management in addition to PA approval.

Typical Documentation for Eylea PA (Ophthalmic Context)

Ophthalmologist's clinical notes detailing diagnosis and treatment plan
Diagnostic imaging (e.g., OCT, fluorescein angiography) confirming indication
Visual acuity measurements and other functional assessments
Documentation of prior anti-VEGF therapy or other treatment history
Patient's medical history relevant to contraindications or risk factors

The Distinct Landscape of Orthopedic Prior Authorization

Orthopedic practices face a high volume of PAs for advanced imaging, surgical procedures, and durable medical equipment. Unlike specialty drugs, orthopedic PAs often require extensive documentation of conservative care trials, specific imaging findings, and adherence to clinical guidelines like AAOS Clinical Practice Guidelines or ACR Appropriateness Criteria. This involves multi-step PA cascades, from imaging to surgery to post-operative DME.

Common Orthopedic PA Categories and Documentation Requirements

**Major Joint Replacement:** Documentation of failed conservative care (NSAIDs, PT, injections), BMI, imaging (e.g., Kellgren-Lawrence grade).
**Spine Surgery:** Conservative care trial (≥6 weeks PT, medications), imaging (MRI showing herniation, stenosis), neurological exam findings.
**Advanced Imaging (MRI/CT):** Clinical exam findings, failed conservative care for non-emergency indications, prior imaging history. Often routed through specialty benefit-management vendors.
**Sports Medicine Procedures:** Conservative care trial, MRI findings (e.g., rotator cuff tear), symptom correlation.
**DME and Bracing:** Medical necessity for complex bracing or CPM machines, sometimes bundled with surgical PA.

Navigating Administrative Complexity Across Diverse Specialties

For health systems encompassing both ophthalmology and orthopedics, the challenge lies in managing two fundamentally different PA workflows. Eylea's PA involves specialty drug formularies and buy-and-bill logistics, while orthopedic PA demands granular clinical detail for procedures and imaging, often with multiple sequential approvals and peer-to-peer reviews. An integrated platform is crucial for standardizing processes and reducing administrative burden across these disparate requirements.

Klivira's Approach to Comprehensive Prior Authorization Automation

Klivira's platform provides a unified solution for managing the full spectrum of prior authorizations, from specialty drugs like Eylea to complex orthopedic procedures. Our EMR integrations, including SMART on FHIR capabilities, automate data extraction for both ophthalmic and orthopedic documentation requirements. This includes tracking conservative care for orthopedic cases and streamlining the submission process for specialty medications, connecting directly to payer portals and X12 278 transactions.

Frequently asked questions

Why is Eylea prior authorization discussed in the context of orthopedics?

While Eylea is an ophthalmic drug, this discussion addresses the administrative challenge faced by multi-specialty health systems that must manage both specialty drug PAs (like Eylea) and the distinct, high-volume prior authorization requirements for orthopedic procedures and imaging within the same operational framework.

What are the typical prior authorization requirements for Eylea (aflibercept)?

PA for Eylea generally requires documentation confirming the ophthalmic indication (e.g., wet AMD, DME, RVO) with supporting diagnostic imaging and clinical notes. Payers often look for evidence of medical necessity, prior treatment history, and adherence to their specific coverage criteria for anti-VEGF therapies.

How does Klivira handle specialty drug PAs like Eylea?

Klivira automates the extraction of relevant clinical data from your EMR for specialty drug PAs, including Eylea. Our platform connects directly to payer portals and leverages ePA standards like NCPDP SCRIPT to streamline submissions, monitor status, and reduce manual effort associated with 'buy-and-bill' medication approvals.

What are the primary PA challenges in orthopedics that Klivira addresses?

Klivira addresses orthopedic PA challenges by automating conservative-care tracking, orchestrating multi-step PA cascades (imaging → surgery → DME), and integrating with specialty benefit-management vendors. We also support documentation for BMI criteria and facilitate peer-to-peer scheduling for complex cases.

Can Klivira integrate with our EMR to manage both Eylea and orthopedic PAs?

Yes, Klivira offers robust EMR integration, including SMART on FHIR, to extract clinical data for both specialty drug PAs and complex orthopedic procedures. This unified integration streamlines data capture and submission for all PA types, centralizing management within a single platform.